To evaluate a 9-month fully oral regimen. Initial trial results from Stage 2 of the trial are expected in 2022. Thirteen Stage 2 sites in Ethiopia, Georgia, India, Moldova, Mongolia, South Africa, and Uganda are participating.

From CT.gov: The STREAM study is an international, multi-centre, parallel-group, open-label, randomised, controlled trial in patients with multi-drug resistant tuberculosis (MDR-TB) including patients with rifampicin-resistant and isoniazid-sensitive TB.